FSD Pharma Submits Clinical Trial to Health Canada
Ticker: QNTM · Form: 6-K · Filed: May 28, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, clinical-trial, health-canada
TL;DR
FSD Pharma submitted a clinical trial to Health Canada, a key step for their drug development.
AI Summary
FSD Pharma Inc. filed a Form 6-K on May 28, 2024, to report its activities for May 2024. The filing includes a press release (Exhibit 99.1) detailing the submission of a clinical trial to Health Canada. The company's Chief Financial Officer, Nathan Coyle, signed the report.
Why It Matters
This submission is a crucial step in FSD Pharma's drug development process, potentially leading to further clinical trials and eventual market approval.
Risk Assessment
Risk Level: medium — Regulatory submissions and clinical trial progress are inherently risky, with outcomes dependent on scientific and regulatory review.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- May 28, 2024 (date) — Filing date
- Nathan Coyle (person) — Chief Financial Officer
- Health Canada (company) — Regulatory body
FAQ
What is the specific clinical trial FSD Pharma submitted to Health Canada?
The filing does not specify the exact clinical trial, only that a submission was made.
What is the expected timeline for Health Canada's review of the clinical trial submission?
The filing does not provide any information regarding the expected timeline for Health Canada's review.
What is the primary business of FSD Pharma Inc.?
FSD Pharma Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is FSD Pharma Inc. headquartered?
FSD Pharma Inc. is headquartered in Toronto, Ontario, Canada.
What other forms does FSD Pharma Inc. file with the SEC?
FSD Pharma Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-05-28 08:15:44
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 18KB
- fsd_ex991img2.jpg (GRAPHIC) — 6KB
- 0001654954-24-006936.txt ( ) — 37KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: May 28, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3